Neuroimaging measures linked to stages of memory impairment
Mar 04, 2022
The presence of Alzheimer’s disease pathology is related to Stages of Objective Memory Impairment in cognitively unimpaired older adults.
More news for Tuesday, Aug. 31
Aug 31, 2021
Groups request extension for vaccine mandate in Maine … Senior housing providers can take action to protect older adults from the end of eviction moratorium … Multiple defendants indicted in ‘grandparent...
CDC data show how small, large assisted living communities differ
By
Lois A. Bowers
Feb 07, 2018
A data brief published Tuesday by the Centers for Disease Control and Prevention’s National Center for Health Statistics sheds light on the differences between smaller and larger assisted living...
Insurance company argues against defending senior living operator in wrongful death suit
By
Kimberly Bonvissuto
Jan 18, 2023
A policy lapse means that an insurer does not have to defend an assisted living community from a wrongful death lawsuit, the insurer is arguing in federal court.
Congressional report slams FDA, drugmaker over approval of Alzheimer’s drug Aduhelm
Dec 29, 2022
The controversy over aducanumab (Aduhelm) stretches back to its June 2021 approval by the US Food and Drug Administration.
Study explores impact of FDA approval of aducanumab on trial participation
Dec 06, 2022
Individuals who were independently aware of the FDA decision demonstrated a reduced willingness to participate.
Racial/ethnic minorities underrepresented in Alzheimer’s neuroimaging research
Jul 28, 2023
Sample diversity has improved recently, with proportion of Blacks increasing from 3.39% in 1994-2017 to 8.29% in 2018-2022.
Solanezumab does not slow cognitive decline in preclinical Alzheimer’s disease
Jul 19, 2023
The mean change in Preclinical Alzheimer Cognitive Composite score not significantly different at 240 weeks with solanezumab or placebo.
Minor neuropsychological deficits indicate risk for progression to Alzheimer’s disease
Oct 13, 2023
For patients with subjective cognitive decline, those with minor neuropsychological deficits have increased cognitive decline and a risk for progression to mild cognitive impairment.
New drug for Alzheimer’s disease shows promise in phase 3 trial
Sep 28, 2022
Lecanemab is a monoclonal antibody drug designed to target and help remove Alzheimer’s-associated amyloid plaques in the brain.